Madrigal Pharmaceuticals posts Q3 2026 earnings beat, shares jump double‑digits
+1 new source since this summary was written
Madrigal Pharmaceuticals reported third‑quarter 2026 revenue of $431.27 million, up 50.1% year‑over‑year, and adjusted diluted EPS of $1.83, reversing a prior‑year loss. The results beat analyst forecasts, prompting the stock to surge more than 10% in pre‑market trading. Management highlighted continued demand for its flagship MASH drug Rezdiffra and announced a new Phase 3 trial.
Why it matters
The earnings beat drove the share price up 14.1% to $491.90, rewarding investors for the stronger‑than‑expected revenue and profitability. Analysts note the beat may reinforce the bullish outlook on Rezdiffra’s growth trajectory.
Key facts
- 1Revenue was $431.27 million, a 50.1% increase from the prior‑year quarter. tradingview.com
- 2Diluted EPS was $1.83, compared with a loss of $4.01 a year earlier. tradingview.com
- 3Net income was $55.44 million versus a net loss of $114.19 million a year earlier. tradingview.com
- 4Rezdiffra generated $1.1 billion in year‑to‑date sales, driving the revenue growth. investing.com
- 5Shares rose 14.1% to $491.90 after the results were released. investing.com
- 6The company announced a new Phase 3 trial for MASH cirrhosis patients. investing.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.